MedTrace Logo

Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia

NCT05863234 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2025-04-30

No results posted yet for this study

Summary

This is Phase I/II Dose-Escalation Study to evaluate the tolerability, safety, efficacy and pharmacokinetics of PPMX-T003 in aggressive NK-cell leukemia.

Conditions

  • Aggressive NK Cell Leukemia

Interventions

DRUG

PPMX-T003

The therapeutic agent is administered continuously intravenously

Sponsors & Collaborators

  • Kyoto University Hospital

    collaborator OTHER

  • Hokkaido University Hospital

    collaborator OTHER

  • Okayama University

    collaborator OTHER

  • Tokai University

    collaborator OTHER

  • Kyushu University

    collaborator OTHER

  • Tohoku University

    collaborator OTHER

  • Nagoya University

    collaborator OTHER

  • Komagome Hospital

    collaborator OTHER

  • Hiroshima University Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-21
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05863234 on ClinicalTrials.gov